GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » EV-to-FCF

Vectus Biosystems (ASX:VBS) EV-to-FCF : -1.57 (As of Jul. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vectus Biosystems's Enterprise Value is A$2.17 Mil. Vectus Biosystems's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.38 Mil. Therefore, Vectus Biosystems's EV-to-FCF for today is -1.57.

The historical rank and industry rank for Vectus Biosystems's EV-to-FCF or its related term are showing as below:

ASX:VBS' s EV-to-FCF Range Over the Past 10 Years
Min: -19.13   Med: 0   Max: 0
Current: -1.07

ASX:VBS's EV-to-FCF is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 8.09 vs ASX:VBS: -1.07

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-07-26), Vectus Biosystems's stock price is A$0.095. Vectus Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.044. Therefore, Vectus Biosystems's PE Ratio for today is At Loss.


Vectus Biosystems EV-to-FCF Historical Data

The historical data trend for Vectus Biosystems's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems EV-to-FCF Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial -9.48 -7.17 -13.71 -9.07 -8.66

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -9.07 - -8.66 -

Competitive Comparison of Vectus Biosystems's EV-to-FCF

For the Biotechnology subindustry, Vectus Biosystems's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's EV-to-FCF falls into.



Vectus Biosystems EV-to-FCF Calculation

Vectus Biosystems's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.174/-1.382
=-1.57

Vectus Biosystems's current Enterprise Value is A$2.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vectus Biosystems's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.095/-0.044
=At Loss

Vectus Biosystems's share price for today is A$0.095.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.044.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Vectus Biosystems EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems Headlines

No Headlines